196300 HLB펩
기본 정보
- 섹터: KOSDAQ:제조
- 시가총액: 436억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 펩타이드 · 바이오 · 신약 · 항암 · 당뇨치료
- 네이버 금융: 🔗
기업개요
- 동사는 2000년 펩타이드 바이오소재 및 혁신 신약개발 전문기업으로 설립되었으며, 2016년 기술성장기업으로 코스닥에 상장함.
- 의약품, 원료의약품, 의약부외품 제조·판매 및 생명공학 관련 연구·기술개발을 하고 있으며, 의약용과 연구용 펩타이드 소재가 주요 매출을 차지함.
- GMP 생산시설을 보유하고 CDMO 서비스를 제공하며, 항균, 암 표적, 당뇨/비만치료 펩타이드 등 신약 파이프라인 구축과 상업화를 추진하고 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | 4,325 | 4,335 | 🔴 +0.23% | — | ×0.4 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-08-06 | 4,300 | 4,325 | 🔴 +0.58% | — | ×0.1 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-08-05 | 4,245 | 4,300 | 🔴 +1.30% | — | ×0.2 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-08-04 | 4,160 | 4,245 | 🔴 +2.04% | — | ×0.1 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-08-03 | 3,980 | 4,160 | 🔴 +4.52% | — | ×0.2 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-31 | 3,745 | 3,980 | 🔴 +6.28% | — | ×0.1 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-30 | 3,855 | 3,745 | 🔵 -2.85% | — | ×0.1 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-07-29 | 3,880 | 3,855 | 🔵 -0.64% | — | ×0.2 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.1 | -0.0 |
| 2026-07-28 | 3,980 | 3,880 | 🔵 -2.51% | — | ×0.2 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-27 | 3,915 | 3,980 | 🔴 +1.66% | — | ×0.5 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-24 | 3,885 | 3,915 | 🔴 +0.77% | — | ×2.1 | 🔻 개인 | -0.9억 | -0.9 | +0.0 | +0.0 | +0.0 | +0.9 | +0.0 |
| 2026-07-23 | 3,715 | 3,885 | 🔴 +4.58% | — | ×0.2 | 🔻 개인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-22 | 3,770 | 3,715 | 🔵 -1.46% | — | ×0.3 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-21 | 3,955 | 3,770 | 🔵 -4.68% | — | ×0.4 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-07-20 | 4,135 | 3,955 | 🔵 -4.35% | — | ×0.8 | 🟢 외인 | +0.7억 | +0.7 | +0.0 | +0.0 | +0.0 | -0.6 | -0.1 |
| 2026-07-16 | 4,900 | 4,135 | 🔵 -15.61% | — | ×6.9 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.4 | +0.0 |
| 2026-07-15 | 3,770 | 4,900 | 🔴 +29.97% | — | ×19.4 | 🔻 개인 | -1.8억 | -1.8 | +0.0 | +0.0 | +0.0 | +2.0 | -0.2 |
| 2026-07-14 | 4,080 | 3,770 | 🔵 -7.60% | — | ×0.8 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-07-13 | 4,010 | 4,080 | 🔴 +1.75% | — | ×1.5 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-10 | 4,680 | 4,010 | 🔵 -14.32% | — | ×5.4 | 🔻 개인 | -0.4억 | -0.4 | +0.0 | +0.0 | +0.0 | +0.4 | +0.0 |
| 2026-07-09 | 4,575 | 4,680 | 🔴 +2.30% | — | ×0.8 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-08 | 4,510 | 4,575 | 🔴 +1.44% | — | ×0.5 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-07-07 | 4,580 | 4,510 | 🔵 -1.53% | — | ×0.2 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-06 | 4,420 | 4,580 | 🔴 +3.62% | — | ×0.9 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-03 | 4,415 | 4,420 | 🔴 +0.11% | — | ×0.4 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | -0.0 | +0.0 | -0.1 | +0.0 |
| 2026-07-02 | 4,560 | 4,415 | 🔵 -3.18% | — | ×1.4 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-07-01 | 4,650 | 4,560 | 🔵 -1.94% | — | ×0.2 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
| 2026-06-30 | 4,605 | 4,650 | 🔴 +0.98% | — | ×0.7 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-06-29 | 4,340 | 4,605 | 🔴 +6.11% | — | ×1.0 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-06-26 | 4,300 | 4,340 | 🔴 +0.93% | — | ×0.7 | 🟢 외인 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.0 | +0.0 |
| 2026-06-25 | 4,595 | 4,300 | 🔵 -6.42% | — | ×0.5 | 🔻 개인 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | +0.0 | +0.0 |
일자별 사유 (최신 위)
2026-07-15
- 사유: —
- 섹터 컨텍스트: KOSDAQ:제조 (smart +1,144억)
- 매크로 원인: HLB 리보세라닙 FDA 제조 리스크 해소 기대에 그룹주 무더기 상한가, 미프진 허가 검토·항암신약 모멘텀 가세 (보통)